Search Menu
People

Dr Charles Harrington

Dr Charles Harrington
Dr Charles Harrington
Dr Charles Harrington

BSc (Hons) (Glasgow, 1977); PhD (Glasgow, 1980)

Senior Research Fellow

About
Email Address
c.harrington@abdn.ac.uk
Telephone Number
+44 (0)1224 438563
Office Address

Liberty Building, Institute of Medical Sciences, Foresterhill Road, Aberdeen AB25 2ZP United Kingdom

School/Department
School of Medicine, Medical Sciences and Nutrition

Biography

Charlie Harrington graduated in Microbiology from Glasgow University where he developed an interest in chemical microbiology and the study of microbial cell walls. He completed his PhD working with Dr Julia Douglas on cell wall synthesis in yeast and followed with a one-year NIH-funded Fellowship with Dr Wilf Arnold in Kansas City, Missouri studying enzymes within the yeast cell envelope. After this, Charlie joined Professor Sir James Baddiley in the Department of Biochemistry at the University of Cambridge as a Research Fellow, where he spent four years investigating the synthesis of bacterial cell wall polymers. Dr Harrington then spent over two years at Murex Medical Research Ltd., Cambridge, developing diagnostic tests for microbial diseases, including methicillin-resistant Staphylococcus aureus and sexually transmitted diseases. This combined monoclonal antibody technology with his knowledge of the microbial cell surface.

In 1988, he joined Claude Wischik working at the Medical Research Council’s Laboratory of Molecular Biology. Working in the Cambridge Brain Bank Laboratory over a period of 10 years. During this time, Wischik, Harrington and colleagues developed an assay for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease. Charlie moved with Professor Wischik, in 1998, to the University of Aberdeen, where he was appointed as a Senior Research Fellow.

The Alzheimer's research was translated to the clinic, through a spin-out company, TauRx Therapeutics, who are conducting phase 3 trials of hydromethylthionine.  Dr Harrington is Chief Scientific Officer for TauRx Therapeutics Ltd responsible for the non-clinical activities of the company.

Qualifications

  • BSc (Hons) Microbiology 
    1977 - University of Glasgow 
  • PhD Microbiology 
    1980 - University of Glasgow 

Latest Publications

View My Publications

Research

Research Overview

Dr Harrington has research interests in the neurodegenerative diseases and, in particular, Alzheimer’s disease. His main focus has been on the biology of tau protein in aging and in Alzheimer’s disease. Dr Harrington’s research is aimed at diseases that are characterised by protein aggregation and methods by which these processes might be prevented.

Publications

Page 3 of 4 Results 51 to 75 of 99

  • Assays for the Screening and Characterization of Tau Aggregation Inhibitors

    Rickard, J. E., Horsley, D., Wischik, C. M., Harrington, C. R.
    Tau Protein: Methods and Protocols. Smet-Nocca, C. (ed.). Springer, pp. 129-140, 12 pages
    Chapters in Books, Reports and Conference Proceedings: Chapters (Peer-Reviewed)

  • Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

    Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., Schelter, B. O., Davis, C. S., Staff, R. T., Bracoud, L., Shamsi, K., Storey, J. M. D., Harrington, C. R., Wischik, C. M.
    The Lancet, vol. 388, no. 10062, pp. 2873-2884
    Contributions to Journals: Articles

  • Inhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer's Disease

    Wischik, C. M., Storey, J. M. D., Wischik, D. J., Harrington, C. R.
    Developing Therapeutics for Alzheimer's Disease: Progress and Challenges. Wolfe, M. S. (ed.). Elsevier Inc., pp. 385-436, 52 pages
    Chapters in Books, Reports and Conference Proceedings: Chapters

  • Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease

    Lai, R. Y. K., Harrington, C. R., Wischik, C. M.
    Biomolecules, vol. 6, no. 2, pp. 1-19
    Contributions to Journals: Articles

  • Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies

    Šimić, G., Babić Leko, M., Wray, S., Harrington, C., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Giovanni, G. D., Wischik, C., Hof, P. R.
    Biomolecules, vol. 6, no. 1, 6
    Contributions to Journals: Review articles

  • Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration

    Melis, V., Zabke, C., Stamer, K., Magbagbeolu, M., Schwab, K., Marshall, P., Weh, R. W., Bachmann, S., Deiana, S., Moreau, P. H., Davidson, K., Harrington, K. A., Rickard, J. E., Horsley, D., Garman, R., Mazurkiewicz, M., Niewiadomska, G., Wischik, C. M., Harrington, C. R., Riedel, G., Theuring, F.
    Cellular and Molecular Life Sciences, vol. 72, no. 11, pp. 2199-2222
    Contributions to Journals: Articles

  • Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models

    Melis, V., Magbagbeolu, M., Rickard, J. E., Horsley, D., Davidson, K., Harrington, K. A., Goatman, K., Goatman, E. A., Deiana, S., Close, S. P., Zabke, C., Stamer, K., Dietze, S., Schwab, K., Storey, J. M. D., Harrington, C. R., Wischik, C. M., Theuring, F., Riedel, G.
    Behavioural Pharmacology, vol. 26, no. 4, pp. 353-368
    Contributions to Journals: Articles

  • Cellular Models of Aggregation-Dependent Template-Directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer's Disease

    Harrington, C. R., Storey, J. M. D., Clunas, S., Harrington, K. A., Horsley, D., Ishaq, A., Kemp, S. J., Larch, C. P., Marshall, C., Nicoll, S. L., Rickard, J. E., Simpson, M., Sinclair, J. P., Storey, L. J., Wischik, C. M.
    The Journal of Biological Chemistry, vol. 290, no. 17, pp. 10862-10875
    Contributions to Journals: Articles

  • The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease

    Flores-Rodríguez, P., Ontiveros-Torres, M. A., Cárdenas-Aguayo, M. C., Luna-Arias, J. P., Meraz-Ríos, M. A., Viramontes-Pintos, A., Harrington, C. R., Wischik, C. M., Mena, R., Florán-Garduño, B., Luna-Muñoz, J.
    Frontiers in Neuroscience, vol. 9, 33
    Contributions to Journals: Articles

  • Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease

    Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., Harrington, C. R.
    Journal of Alzheimer's Disease, vol. 44, no. 2, pp. 705-720
    Contributions to Journals: Articles

  • Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease

    Baddeley, T. C., McCaffrey, J., Storey, J. M. D., Cheung, J. K. S., Melis, V., Horsley, D., Harrington, C. R., Wischik, C. M.
    Journal of Pharmacology and Experimental Therapeutics, vol. 352, no. 1, pp. 110-118
    Contributions to Journals: Articles

  • Tau-aggregation inhibitor therapy for Alzheimer's disease

    Wischik, C. M., Harrington, C. R., Storey, J. M. D.
    Biochemical Pharmacology, vol. 88, no. 4, pp. 529-539
    Contributions to Journals: Articles

  • TauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX

    Wischik, C. M., Harrington, C. R., Storey, J. M. D.
    13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, pp. S26
    Contributions to Journals: Abstracts

  • Calcyclin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: neuronal localization and possible function

    Wasik, U., Schneider, G., Mietelska-Porowska, A., Mazurkiewicz, M., Fabczak, H., Weis, S., Zabke, C., Harrington, C. R., Filipek, A., Niewiadomska, G.
    Neurobiology of Aging, vol. 34, no. 5, pp. 1380-1388
    Contributions to Journals: Articles

  • New phenothiazine diaminium compounds are tau protein aggregation inhibitors, useful to treat e.g. Alzheimer's disease, Pick's disease, progressive supranuclear palsy, frontotemporal dementia and frontotemporal lobar degeneration syndromes

    Baddeley, T., Clunas, S., Harrington, C. R., Horsley, D., Ishaq, A., Khan, K., Loh, Y. S., Marshall, C., Rickard, J. E., Simpson, M., Sinclair, J. P., Storey, J. M. D., Williamson, C., Wischik, C. M., Wood, B. A.
    Patents: Patents

  • The molecular pathology of Alzheimer's disease

    Harrington, C. R.
    Neuroimaging Clinics of North America, vol. 22, no. 1, pp. 11-22
    Contributions to Journals: Literature Reviews

  • 3,7-diamino-10H-phenothiazine salts and their use: WO2007110627

    Wischik, C. M., Rickard, J. E., Harrington, C. R., Horsley, D., Storey, J. M. D., Marshall, C., Sinclair, J. P., Baddeley, T.
    Patents: Patents

  • Stripline resonator and preamplifier for preclinical magnetic resonance imaging at 4.7 T

    Lavdas, I., Seton, H., Harrington, C. R., Wischik, C. M.
    Magnetic Resonance Materials in Physics, Biology and Medicine, vol. 24, no. 6, pp. 331-337
    Contributions to Journals: Articles

  • 3,6-Disubstituted xanthylium salts

    Clunas, S., Storey, J. M. D., Horsley, D., Rickard, J. E., Harrington, C. R., Wischik, C. M.
    Patents: Patents

  • Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC): methods of treatment of a tauopathy condition comprising the use of thioninium compounds

    Wischik, C. M., Rickard, J. E., Harrington, C. R., Horsley, D., Storey, J. M. D., Marshall, C., Sinclair, J. P.
    Patents: Patents

  • Ligands for aggregated tau molecules: WO2010034982

    Kemp, S. J., Storey, J. M. D., Rickard, J. E., Harrington, C. R., Horsley, D., Wischik, C. M., Clunas, S., Heinrich, T.
    Patents: Patents

  • Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies

    Wischik, C. M., Wischik, D. J., Storey, J. M. D., Harrington, C. R.
    Emerging drugs and targets for Alzheimer's disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism. Martinez, A. (ed.), pp. 210-232, 23 pages
    Chapters in Books, Reports and Conference Proceedings: Chapters

  • Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe

    Mukaetova-Ladinska, E. B., Xuereb, J. H., Garcia-Sierra, F., Hurt, J., Gertz, H. J., Hills, R., Brayne, C., Huppert, F. A., Paykel, E. S., McGee, M. A., Jakes, R., Honer, W. G., Harrington, C. R., Wischik, C. M., CC75C Collaboration Group
    The Scientific World Journal, vol. 9, pp. 1463-1475
    Contributions to Journals: Articles

  • What is the molecular pathology that underlies hippocampal memory decline?

    Harrington, C. R.
    Journal of Neurology, Neurosurgery & Psychiatry, vol. 80, no. 7, pp. 703
    Contributions to Journals: Editorials

  • Therapeutic Use of Diaminophenothiazines: WO2009044127

    Wischik, C. M., Damon J., W., Storey, J. M. D., Harrington, C. R.
    Patents: Patents
Show 10 | 25 | 50 | 100 results per page

Refine

Chapters in Books, Reports and Conference Proceedings

Contributions to Journals

Patents

Update